Skip to main content
Login
Contact
Subscribe
Search form
Search
The Sweetwater Reporter
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Adverum Biotechnlgs
(NQ:
ADVM
)
5.205
USD
-0.015 (-0.29%)
Streaming Delayed Price
/ Updated:
10:20 AM EDT, Oct 17, 2018
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
46,946
Open
5.190
Bid (Size)
5.200 (5)
Ask (Size)
5.250 (3)
Prev. Close
5.220
Today's Range
5.060 - 5.590
52wk Range
2.850 - 8.590
Shares Outstanding
62,271,901
Dividend Yield
N/A
Performance
YTD
+42.60%
+42.60%
1 Month
-11.78%
-11.78%
3 Month
-1.33%
-1.33%
6 Month
-22.31%
-22.31%
1 Year
+40.68%
+40.68%
Top News
More News
Adverum Biotechnologies Announces Data Presented at the European Society of Gene and Cell Therapy (ESGCT)
Today 9:00 EDT
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced data presented at the ESGCT 26th...
Read More
from
GlobeNewswire News Releases
Consolidated Research: 2018 Summary Expectations for Mimecast, Shiloh Industries, Adverum Biotechnologies, AngioDynamics, Kimball Electronics, and Changyou — Fundamental Analysis, Key Performance Indi
October 16, 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Mimecast Limited...
Read More
from
GlobeNewswire News Releases
More News
Read More
Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
September 19, 2018
from
GlobeNewswire News Releases
Adverum to Present at Cantor Global Healthcare Conference
September 18, 2018
from
GlobeNewswire News Releases
Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration
August 29, 2018
from
GlobeNewswire News Releases
Adverum Biotechnologies Receives Orphan Drug Designation for ADVM-053, a Novel Gene Therapy Candidate for the Treatment of Hereditary Angioedema
August 24, 2018
from
GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies — Discovering Underlying Factors of In
August 20, 2018
from
GlobeNewswire News Releases
Adverum Biotechnologies Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 08, 2018
from
GlobeNewswire News Releases
Analysts Expect PZI Will Reach $23
October 05, 2018
category
ETFs
from
ETF Channel
ADVM Makes Notable Cross Below Critical Moving Average
September 24, 2018
category
Stocks
from
Market News Video
Cantor Fitzgerald's 7 Buys For 7 Biotechs
September 21, 2018
category
Market News
,
CARA
,
General
, and 15 more.
from
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
